Navigation Links
Aspirin Doesn't Guard Diabetics Against Heart Disease

Second study found vitamins E, C did little to protect healthy men, either

SUNDAY, Nov. 9 (HealthDay News) -- Two large studies released Sunday cast doubt on the cardiac benefits of either low-dose aspirin or vitamin supplements.

First, Japanese researchers found that low-dose aspirin did not reduce the risk of cardiovascular events in people with type 2 diabetes.

Second, Harvard researchers concluded that neither vitamin E nor vitamin C reduced the risk of major cardiovascular events in a group of low-risk, middle-aged male physicians.

People with diabetes are at a much higher risk for cardiovascular events, and the American Diabetes Association recommends the use of aspirin as a primary prevention measure. However, there is scant evidence to support the recommendations, said researchers from Kumamoto University in Japan.

The JPAD trial randomized 2,539 Japanese patients with type 2 diabetes with no history of atherosclerotic disease to receive low-dose aspirin (81 or 100 milligrams per day) or to be in a non-aspirin control group.

While aspirin resulted only in a slight reduction in the risk of coronary, cerebrovascular and peripheral vascular events in participants, it did reduce combined fatal coronary and cerebrovascular events.

Among volunteers aged 65 or older, there was a borderline significant reduction (32 percent) in the risk of coronary, cerebrovascular and peripheral vascular events.

The study leaves a number of questions unanswered, experts said.

"We have to wait for more studies," said Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City. "I also don't know if we can use this data to extrapolate to an American population."

"There was a trend for cardiovascular event reduction, but not even close to being statistically significant, and also significantly lower fatal events, but again very few," said Dr. Carl J. Lavie, medical director of cardiac rehabilitation at Ochsner Heart & Vascular Institute in New Orleans. "For some, the diabetes mellitus population does not seem to be gaining the expected aspirin benefit, at least in primary prevention. Certainly, there is proven aspirin benefit in secondary prevention. Right now, it would be hard to make a very strong case for low-dose aspirin, at least in the relatively healthy diabetic in primary prevention."

Indeed, the study authors themselves said that the role of aspirin as primary prevention in patients with type 2 diabetes is yet to be understood.

As with aspirin in the diabetic population, vitamin E and C supplements are widely used to prevent cardiovascular events, again without strong evidence to support the practice in low-risk individuals.

In the second study, 14,641 U.S. male doctors aged 50 or older were randomly assigned to receive 400 IU of vitamin E every other day and 500 milligrams of vitamin C every day or a placebo at the same intervals. The vast majority of participants had no history of cardiovascular disease.

After a mean follow-up of eight years, the researchers determined that neither vitamin had an effect on the incidence of major cardiovascular events or death, when compared with a placebo. This was true even of the 5.1 percent of men who had a history of cardiovascular disease.

There was, however, a 74 percent increase in the risk of hemorrhagic (bleeding) stroke among men in the vitamin E group.

"Based on this and other studies, there is absolutely no reason for patients to be taking E for cardioprotection, and if they are doing so, we should encourage them to stop, as I have been doing for the last five years or so," Lavie said. "The jury has still been out about C, but this certainly indicates no benefit, although no definite harm."

A representative for the supplements industry took a different view.

"Although the results did not demonstrate an overall benefit [for vitamins E and C], the results also do not discount the earlier epidemiological data showing that people with high intakes of vitamins E and C may have a lower risk of cardiovascular disease," Andrew Shao, vice president of scientific and regulatory affairs at the Council for Responsible Nutrition, said in a statement.

"Nutrition research is extremely complex," Shao added, "and doesn't always provide clear-cut answers. This study raises an interesting set of scientific challenges as to why the benefits found in observational studies have not been confirmed in this kind of trial."

Both studies were expected to be published in the Nov. 12 issue of the Journal of the American Medical Association and were released early to coincide with presentations on Sunday at the American Heart Association's annual scientific sessions, in New Orleans.

Other research from the meeting showed that both traditional and novel nutritional strategies could reduce risk factors for heart disease.

Drinking three cups a day of hibiscus tea (found in most commercial tea blends in the United States) lowered blood pressure over a six-week period, most significantly among those with the highest blood pressure to begin with, Diane McKay, an assistant professor at Tufts University, said during a Sunday news conference. "Even small changes in blood pressure...when seen in large population studies, will effectively reduce the risk of certain mortalities," she said.

Other research showed that three servings of non-soy legumes such as beans and chickpeas lowered total and LDL ("bad") cholesterol, according to a meta-analysis of previous studies. "My Pyramid suggests three cups weekly of dry beans and peas, or legumes, and we are very, very far behind," said Dr. Lydia A.L. Bazzano, of Tulane University in New Orleans.

Two additional studies found that eating high-fat diets increased left-ventricular mass, which is linked to left ventricular dysfunction, a predictor for heart failure, while diets high in fruits, vegetables and fish had the opposite effect, said researchers at Drexel University School of Public Health in Philadelphia.

More information

Visit the American Diabetes Association for more on the link between type 2 diabetes and heart disease.

SOURCES: Suzanne Steinbaum, D.O., director, women and heart disease, Lenox Hill Hospital, New York City; Carl J. Lavie, M.D., medical director, cardiac rehabilitation, Ochsner Heart & Vascular Institute, New Orleans; Nov. 9, 2008, presentations, American Heart Association's annual scientific session, New Orleans; news release, Nov. 9, 2008, Council for Responsible Nutrition, Washington, D.C.; Nov. 12, 2008, Journal of the American Medical Association; Nov. 9, 2008, news conference with Diane McKay, Ph.D., assistant professor, Tufts University, Boston, and Lydia A.L. Bazzano, M.D., Ph.D., Tulane University, New Orleans

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes
2. Bayer Marketing Two Unapproved Aspirin Products: FDA
3. New CHARISMA Outcome Study Results Validate Aspirin Effect
4. Breakthrough Testing for Patients on Aspirin Therapy for Preventing Heart Attacks
5. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
6. Aspirin at Bedtime Lowers Blood Pressure
7. Anti-Clotting Drug as Good as Aspirin at Stopping Second Stroke
8. Daily Aspirin May Reduce Breast Cancer Risk
9. Daily aspirin may reduce risk of common type of breast cancer
10. Aspirin-like compounds increase insulin secretion in otherwise healthy obese people
11. Will botox be the aspirin of the 21st century?
Post Your Comments:
Related Image:
Aspirin Doesn't Guard Diabetics Against Heart Disease
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology: